Evotec SE appointed Dr. Joanna Holbrook as Chief Scientific Officer and a Member of the Management Board, effective November 1, 2026. Most recently, she served as Therapy Area Head, Cardiovascular, Renal and Hepatic Disease and Head of in vitro Discovery Platforms at Novo Nordisk. Her previous roles include Chief Scientific Officer at Biomodal, Vice President, Translational Medicine at BenevolentAI, Professor of Bioinformatics at the University of Southampton, and Senior Principal Investigator at the Singapore Institute for Clinical Sciences. She also served as an adjunct Professor at the National University of Singapore.
Evotec SE’s joint reporting persons disclosed that Ninety Fourth Investment Company sold 11,481,502 Ordinary Shares at a gross price of EUR 2.5109 per share and one ADS at a net price of $1.56 per ADS on October 9, 2026, in a privately negotiated block trade. The reporting persons said the sale was undertaken to completely divest their investment in Evotec.
Mubadala Investment Company, Mamoura Diversified Global Holding and Ninety Fourth Investment Company ceased to beneficially own more than 5% of the class on October 9, 2026. Mubadala Technology Investments and ATIC Second International Investment Company ceased to beneficially own more than 5% on July 29, 2022. Each of the five reporting persons is listed with 0.00 Ordinary Shares beneficially owned and 0.0% of the class. The ownership calculation uses 177,909,968 Ordinary Shares outstanding as of October 9, 2026; each ADS represents one-half of one Ordinary Share.
Evotec SE (EVO) announced preliminary, unaudited Group revenue of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million for the first nine months of 2026. The company said these figures were above current market expectations, with the variance driven largely by the phasing of consensus estimates.
Evotec reaffirmed full-year 2026 guidance: Group revenue of approximately €570 million to €610 million (€595 million to €635 million at CER) and adjusted Group EBITDA of approximately -€70 million to -€105 million (-€60 million to -€90 million at CER). Full third-quarter and nine-month results are scheduled for publication on November 5, 2026.
Evotec SE announced that Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026, by mutual consent between Dr. Dohrmann and the company. He has served as Chief Scientific Officer and a member of the Management Board since 2010, and CEO Dr. Christian Wojczewski thanked him for 16 years of contributions. The search for a replacement is ongoing. Dr. Wojczewski said Dr. Dohrmann helped establish capabilities in iPSC-based technologies and omics, and described the scientific infrastructure he built as an essential component of Evotec’s future growth and profitability. Dr. Dohrmann said he was grateful for colleagues’ support and collaboration and looked forward to Evotec’s scientific expertise continuing to create value for customers, partners and patients.
Evotec SE (EVO) reported that its wholly owned biologics CDMO subsidiary, Just – Evotec Biologics, has initiated a Phase 1 clinical trial of JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses. The program was developed under the U.S. Department of War’s Accelerated Antibodies Program, moving from antibody sequence selection through preclinical development, process development, regulatory submission and cGMP manufacture of clinical material at the J.POD® facility in Redmond, Washington using a continuous bioprocessing platform.
The orthopoxvirus program is the second awarded to Just – Evotec Biologics under this U.S. government framework and, together with an earlier 2022 plague antibody program, has a combined potential contract value of up to $123.9 million. JST-018 is being developed as a prophylactic therapy intended to help protect warfighters at elevated risk of exposure to biological threats, and the Phase 1 study is listed on ClinicalTrials.gov under identifier NCT07595458.
Evotec SE reports a weak first half of 2026, with Group revenue down 19.2% to €300.1 m from €371.2 m, reflecting softer customer demand, weaker sales-to-revenue conversion and the non-repeat of a large Sandoz license deal. At constant exchange rates, revenue was €313.2 m. Gross margin turned to (1.0)% from 13.6%, as underutilisation in Discovery & Preclinical Development (D&PD) and negative mix effects in Just – Evotec Biologics (JEB) weighed on profitability.
Other operating expenses surged to €51.2 m, including a €42.3 m impairment on a Hamburg lab building, and reorganization costs linked to Project Horizon reached €98.9 m. Adjusted Group EBITDA declined to a loss of €42.7 m versus a €1.9 m loss a year earlier, and net loss widened to €168.6 m from €75.1 m. Operating cash flow was negative €111.1 m. These effects were partly offset by a €71.9 m gain from the sale of Tubulis GmbH and tight control of R&D and SG&A spending.
Total liquidity stood at €465.6 m, supported by €116.1 m of new senior unsecured convertible bonds to finance Horizon. The equity ratio fell to 42.3%. Updated 2026 guidance now targets revenue of €570–610 m and adjusted EBITDA of €(70) to €(105) m, materially below previous ranges, mainly due to lower-than-expected strategic partnership and milestone contributions, with some revenues shifting into 2027.
Evotec SE filed a Form 6-K as a foreign private issuer to report a directors’ dealing by Dr. Cord Dohrmann. The filing states that on June 16, 2026, the company submitted a directors’ dealing notice for a transaction in which Dr. Dohrmann sold shares, detailed in Exhibit 99.1. This is an administrative disclosure and does not include financial results or guidance.
Evotec SE reported a sharp downturn in first‑quarter 2026 results while advancing a major restructuring and strategic review. Group revenue fell 21.7% to €156.6 million, or €166.9 million at constant exchange rates, mainly because Q1 2025 included a large Sandoz license payment and markets for early discovery remained soft.
Cost controls reduced R&D to €10.1 million and SG&A to €43.8 million, but a €75.0 million reorganization charge under the Horizon program pushed operating loss to €121.4 million and net loss to €121.9 million, or €0.69 per share. Adjusted Group EBITDA swung from €3.1 million profit to a €21.9 million loss.
Horizon aims to streamline Evotec’s footprint to ten sites and deliver about €75 million of structural annual savings by the end of 2027, with 20–30% expected in 2026. Despite the loss, liquidity remained sizeable at €444.8 million. After quarter‑end, Evotec agreed to receive about $100 million upfront, plus up to $58 million in milestones, from the sale of its minority stake in Tubulis to Gilead, and installed a new CFO and COO. Full‑year 2026 guidance was reaffirmed.
Evotec SE received an updated ownership and cooperation disclosure from MAK Capital Fund and related parties. The group reports beneficial ownership of 12,681,898 Ordinary Shares, representing about 7.1% of Evotec’s 177,877,782 outstanding Ordinary Shares and ADS-equivalent shares as of May 1, 2026.
MAK Fund bought these shares in open-market transactions for an aggregate purchase price of approximately 73,333,274 euros, excluding commissions. MAK and Evotec entered into a cooperation agreement on April 29, 2026, under which Evotec will nominate Dr. Wolfgang Hofmann to its Supervisory Board at the June 11, 2026 AGM, and the agenda includes increasing the Supervisory Board from six to seven members. MAK Fund agreed to customary voting and cooperation commitments, including supporting board expansion and the issuer’s nominees for the open seats.